|Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2022: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2021: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|Outline of Research at the Start
We will establish the new therapy for specific killing of EHEC infection together with suppression of Shiga toxin expression by designing CRISPR-Cas13a that recognizes stx genes, synthesizing antibacterial capsids, and verifying the cytotoxic and therapeutic effect of antibacterial capsids .